Table 1.
Immunologic phenotyping and post-HCT monitoring over time.
| Pre-HCT | Post-HCT | Age-appropriate ranges | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | 2 weeks | 1-2 months | 3-4 months | 7-8 months | 9-10 months | 12 -14 months | 18-24 months | 36-38 months | 41-52 months | 0-3 months | 12-18 months | 24-72 months |
| Time from HCT | 28 days | 6 months | 12 months | 24 months | 36 months | |||||||
| WBC (cell/μL) | 9,400 | 5,110 (L) | 11,100 | 8,530 | 10,100 | 7,240 | 11,200 | 6,130 | 4,230 | 7,200 - 18,000 | 6,400 - 12,000 | 5,200 - 11,000 |
| Eosinophils (cell/μL) | 9/6/00 | 1,110 (H) | 3890 (H) | 530 | 190 | 180 | 440 | 200 | 100 | Mean 300 | ||
| Lymphocyte Subsets | ||||||||||||
| Lymphocyte (cell/μL) | 1,281 (L) | 1896 (L) | 5,134 | 1,380 (L) | 6,736 | 2,765 | 1,010 | 1,858 | 1,975 | 3,400 - 7,600 | 3,600 - 8,900 | 2,300 - 5,400 |
| CD3+ T (cell/μL) | 8 (L) | 322 (L) | 2,540 | 341 (L) | 4,126 | 1,193 | 580 | 799 | 786 | 2,500 - 5,500 | 2,100 - 6,200 | 1,400 - 3,700 |
| CD4+ T (cell/μL) | 4 (L) | 230 (L) | 870 | 189 (L) | 1,336 | 517 | 264 | 421 | 424 | 1,600 - 4,000 | 1,300 - 3,400 | 700 - 2,200 |
| CD8+ T (cell/μL) | 6 (L) | 24 (L) | 1,446 | 78 (L) | 2,726 | 605 | 262 | 331 | 295 | 560 - 1,700 | 620 - 2,000 | 490 - 1,300 |
| CD19+ B (cell/μL) | 501 | 815 | 1,592 | 552 | 1,547 | 798 | 91 | 771 | 920 | 300 - 2,000 | 720 - 2,600 | 390 - 1,400 |
| CD56+ NK (cell/μL) | 747 | 725 | 905 | 434 | 900 | 724 | 326 | 271 | 257 | 170 - 1,100 | 180 -920 | 130 - 720 |
| CD4+CD45 RA+ cell/μL (% of CD4+) | 1 (L) (0.4%) | 25 (L) (1%) | 1 (L) (0.5%) | 73 (L) (14%) | 17 (L) (6%) | 43 (L) (10.2%) | 1,200 - 3,700 | 1,000 - 2,900 | 430 -1,500 | |||
| CD8/CD45 RA+ cell/μL (% of CD4+) | 2 (L) (8.3%) | 25 (L) (1.7%) | 5 (L) (6%) | 163 (L) (27%) | 110 (L) (42%) | 111 (33.5%) | 450 - 1,500 | 490 - 1,700 | 380 - 1,100 | |||
| Immunoglobulins (mg/dL) | ||||||||||||
| IgG | 994 (on IgRT) | 952 (on IgRT) | 719 (on IgRT) | 630 (on IgRT) | 1120 (on IgRT) | 1050 (on IgRT) | 591 (on IgRT) | 927 (on IgRT) | 487 (off IgRT) | 251 - 906 | 345 - 1213 | 424 - 1,236 |
| IgM | 22 | 13 (L) | 27 | 17 (L) | 68 | 68 | 46 | 20 - 87 | 43 - 173 | 48- 196 | ||
| IgE | <2 | 2.96 | 23.4 (H) | 11.3 (H) | 0.18 - 3.76 | 0.8 - 15.2 | 0.31 - 68.1 | |||||
| IgA | <7 | <7 | <7 | <7 | 65 | 162 | 115 | 1.3 - 53 | 14 - 106 | 14-154 | ||
| Lymphocyte proliferation - EdU (thymidine analog) incorporation method | ||||||||||||
| Lymphocyte viability, LPM | 37.2 (L) | 47.2 (L) | 57.2 (L) | >74.9% | ||||||||
| PWM-induced, CD45 | 5.5 | 12.9 | 23 | >4.4% | ||||||||
| PWM-induced, CD3 | 30.2 | 48.6 | 38.5 | >3.4% | ||||||||
| PWM-induced, CD19 | 1.5 (L) | 6 | 22.4 | >3.8% | ||||||||
| PHA-induced, CD45 | 9.9 (L) | 58.8 | 50.4 | >49.8% | ||||||||
| PHA-induced, CD3 | 33.1 (L) | 78.6 | 68.1 | >58.4% | ||||||||
| Chimerism by STR | ||||||||||||
| WB % donor | 31 | 14 | 10 | 8 | 12 | |||||||
| WB Myeloid cell % donor | 2 | 2 | 2 | 2 | 3 | |||||||
| WB T cell % donor | 94 | 95 | 98 | 98 | 100 | |||||||
| WB B cell % donor | 0 | 1 | 4 | 1 | ||||||||
| WB NK cell % donor | 2 | 21 | 21 | 12 | ||||||||
CT, count; H, high; IgRT, immunoglobulin replacement therapy; L, low; PHA, phytohemaglglutinin; PWM, pokeweed mitogen; STR, short tandem repeat; WBC, white blood cell; WB, whole blood.